U.S. health-care products giant Johnson & Johnson (JNJ) said Tuesday it has acquired nearly all of the shares of Dutch biotechnology company Crucell NV (CRXL, CRXL.AE).

J&J said it has acquired 98.89% of the vaccine maker's stock as of the expiration of its offering period. In correlation, Crucell plans to delist its shares on Euronext Amsterdam and the Swiss Exchange as well as its American depositary shares on the Nasdaq Global Market Select "as soon as reasonably practicable."

Johnson & Johnson had noted in February that 95% of Crucell's issue share capital was either tendered in the offer or was spoken for by J&J through its own holdings or options to buy them.

J&J in December formally launched its EUR1.75 billion takeover offer for Crucell. The companies had said in October they had reached an agreement in principle on J&J's offer for the portion of the Dutch vaccine maker it didn't already own.

In February, Crucell's second-biggest shareholder, Van Herk Group, said it intended to tender its shares to the bid.

Shares of Johnson & Johnson closed at $60.71 and were inactive after-hours. The stock has fallen 5.4% in the past year. Crucell's ADS closed at $34 and were inactive after-hours.

 
   By Nathan Becker, Dow Jones Newswires; 212-416-2855; nathan.becker@dowjones.com 
 
 
Crucell NV ADS, Each Representing One Ordinary Share (MM) (NASDAQ:CRXL)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 Crucell NV ADS, Each Representing One Ordinary Share (MM) 차트를 더 보려면 여기를 클릭.
Crucell NV ADS, Each Representing One Ordinary Share (MM) (NASDAQ:CRXL)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 Crucell NV ADS, Each Representing One Ordinary Share (MM) 차트를 더 보려면 여기를 클릭.